RANKL expression is related to treatment outcome of patients with localized, high-grade osteosarcoma - Wikidata - awgldk - TriplyDB

RANKL expression is related to treatment outcome of patients with localized, high-grade osteosarcoma

RANKL expression is related to treatment outcome of patients with localized, high-grade osteosarcoma

http://www.wikidata.org/entity/Q57226639

about

RANK-RANKL signalling in cancer Targeted immunotherapy for pediatric solid tumors Present Advances and Future Perspectives of Molecular Targeted Therapy for Osteosarcoma Anti-RANKL therapy for bone tumours: Basic, pre-clinical and clinical evidences Components of the RANK/RANKL/OPG system, IL-6, IL-8, IL-16, MMP-2, and calcitonin in the sera of patients with bone tumors.Role of RANK and Akt1 activation in human osteosarcoma progression: A clinicopathological study.Human mesenchymal stem cells as delivery of osteoprotegerin gene: homing and therapeutic effect for osteosarcoma.Bone Sarcomas in Pediatrics: Progress in Our Understanding of Tumor Biology and Implications for Therapy.Receptor activator of nuclear factor κB expression is a prognostic factor in human osteosarcoma.Receptor-Activator of Nuclear KappaB Ligand Expression as a New Therapeutic Target in Primary Bone Tumors.Predicting chemosensitivity in osteosarcoma prior to chemotherapy: An investigational study of biomarkers with immunohistochemistry.Rank ligand as a target in musculoskeletal neoplasms.RANK Ligand Modulation of Autophagy in Oral Squamous Cell Carcinoma Tumor Cells Deciphering signaling networks in osteosarcoma pathobiology.RANK and RANK ligand expression in primary human osteosarcoma.Of dogs and men: comparative biology as a tool for the discovery of novel biomarkers and drug development targets in osteosarcoma.Drugs targeting the bone microenvironment: new therapeutic tools in Ewing's sarcoma?Current therapeutic strategies and novel approaches in osteosarcoma.Bone microenvironment signals in osteosarcoma development.Drugs in early clinical development for the treatment of osteosarcoma.Bisphosphonates inhibit osteosarcoma-mediated osteolysis via attenuation of tumor expression of MCP-1 and RANKL.Co-expression of CD44+/RANKL+ tumor cells in the carcinogenesis of oral squamous cell carcinoma.Bone sarcomas: from biology to targeted therapies.Mapping protein signal pathway interaction in sarcoma bone metastasis: linkage between rank, metalloproteinases turnover and growth factor signaling pathways.Current and future therapeutic approaches for osteosarcoma.Prognostic Value of Osteoprotegerin and sRANKL in Bronchoalveolar Lavage Fluid of Patients with Advanced Non-small Cell Lung Cancer.Receptor Activator of Nuclear Transcription Factor NF-κB (RANK), Its Ligand RANKL, and Natural Inhibitor of RANKL Osteoprotegerin (OPG) in the Blood Serum of Patients with Primary Bone Tumors.Prognostic role of nuclear factor/IB and bone remodeling proteins in metastatic giant cell tumor of bone: A retrospective study.Gene expression profiles and pathway enrichment analysis of human osteosarcoma cells exposed to sorafenib.RANKL blockade prevents and treats aggressive osteosarcomas.

P2860

Q26747442-E89A390F-FD1E-427E-B8C0-31B9E113AE6C Q26747703-2C3078C5-7AD7-4E04-AF48-758CA2C92297 Q26750631-FDF31FEA-3F23-4219-A990-ED9EF71B4789 Q26863493-F298D29F-852E-46EE-A9AC-99F18362ED17 Q33275358-A983C1BF-B4D8-4D13-AB5B-2F37DE51BAAE Q33744585-FCC7DD06-4A7B-4FFE-ADD3-BF26BE5474FB Q35115283-8B3D843C-C8C3-40E6-BC85-8D3E10FB9C60 Q35894540-ACBC8B93-AB35-41CD-92ED-65684A6B4D03 Q35944318-1ED7A740-AC3A-4D29-9C18-7AEF2A31A952 Q36013086-C7C8F2CF-FAC8-41A7-9F02-BBC7DBDC860C Q36075947-A725F53A-FE23-4691-B09F-DEC357E00A48 Q36240919-A67FC3F9-11DA-4F78-9F8B-D86AAE7A40B7 Q36362955-57D7D404-6D08-4A94-A103-6E64AA4AC830 Q37106930-EEBD53BC-C692-497A-BD30-611679459328 Q37179783-1C38FF4E-436F-49B3-AAEA-0BDAA148D62F Q37944599-185C8DE0-1E4C-4FAE-A6CD-3D6D27E5AE77 Q38129954-BA8E5EB2-22F2-4B85-AD9D-8E2232771144 Q38161735-5B6B8207-1F9F-445C-8A52-B4286AD013F7 Q38454980-0AE55E00-601D-4B31-A708-15453522A994 Q38955517-F4B942E1-0295-4FB0-9A7A-0D17F2938BD8 Q39032864-5944D5EE-4ABC-413A-B684-63A392C81864 Q39104687-C5BBD4D4-59D8-427A-BE25-998EDF91A0D9 Q41923624-25337E67-E8A6-497B-84C0-B549A3E01D1A Q46658880-A7C6CFBE-F42F-44C2-8E04-CD4AF8C416E9 Q47360357-B92CEDFF-5799-4A52-9F6E-A87DE78CF70E Q47738511-73A2BD24-E58F-441A-8AB1-024E37BCBD1C Q52757516-EF0D7FA7-EC48-4F8E-8E70-E9A2954D4030 Q53586132-A7773AF6-27BB-4AAD-A25C-5D7A7E7A9637 Q53823554-5A9E113E-59FE-4838-9331-FE0F302470E3 Q54228752-9DE1F38E-D38E-4D21-B7C1-1A249D4E6520

P2860

RANKL expression is related to treatment outcome of patients with localized, high-grade osteosarcoma

http://www.wikidata.org/entity/Q57226639

description

im Mai 2011 veröffentlichter wissenschaftlicher Artikel

@de

wetenschappelijk artikel

@nl

наукова стаття, опублікована в травні 2011

@uk

name

RANKL expression is related to ...... lized, high-grade osteosarcoma

@en

RANKL expression is related to ...... lized, high-grade osteosarcoma

@nl

type

label

RANKL expression is related to ...... lized, high-grade osteosarcoma

@en

RANKL expression is related to ...... lized, high-grade osteosarcoma

@nl

prefLabel

RANKL expression is related to ...... lized, high-grade osteosarcoma

@en

RANKL expression is related to ...... lized, high-grade osteosarcoma

@nl

P1433

Q57226639-96874B64-7412-4A51-933D-C6360325C795

P1476

Q57226639-4F32CFDC-21F6-4C3D-B0E1-B35E1FC5DC67

P2093

Q57226639-1F5B9088-8968-4EAD-A3EB-3A5D762C3860

Q57226639-27A1461B-0586-4420-940E-FDD1616859DF

Q57226639-76E3B7D3-86DD-4AA8-A713-6321CD124239

Q57226639-7809653D-A5FD-4289-9165-053B366578E1

Q57226639-95408F6B-731B-42DD-8CF8-343A942EF03A

Q57226639-A051D652-7C5B-408D-BE94-755B79AA545F

Q57226639-A33F3344-BFAA-407E-B726-2485650DB10F

Q57226639-A66A1245-86C6-4027-8820-16FA7038909F

Q57226639-AF0A24FE-1708-4C71-B6F4-E0238A9330C2

Q57226639-CFFB3B0A-D57D-4254-9DCB-1FA659DE0EB5

P2860

Q57226639-16E34CE9-7505-449D-94B7-629C8AEB9EAB

Q57226639-20AF79FB-5E46-475F-8CD4-45A78529AFFE

Q57226639-4B6E5C59-207D-4F59-B9C2-E154DC4AB8E0

Q57226639-4FD0D83F-1A9E-4B0E-9AD2-C9A17B954AFE

Q57226639-530EF8E1-2DBE-4012-B245-4D53679D9FB8

Q57226639-549A1512-A35B-4AD0-9CC1-5CFFAD90D9B7

Q57226639-56D7F927-9879-498F-8970-FDEC27710621

Q57226639-7CDEB920-6554-418B-A928-5DF4B3910321

Q57226639-7EA2E77F-D598-441D-9F29-55F20C3A7B10

Q57226639-8432BDE9-17E9-403A-943F-061D6E21FCF6

P304

Q57226639-7793BFBF-60C2-4C27-96C0-8F0710C1EDB8

P31

Q57226639-C24BDD7F-FFA4-4607-B009-F4E02CE5DC46

P356

Q57226639-6A6AE80B-610F-44C7-8594-DB9BFC260ED3

P407

Q57226639-19819296-92E5-43E0-89D3-29B495CE28FF

P433

Q57226639-E2C24D58-AE9C-4972-BE87-B26C4613F2D9

P478

Q57226639-B7BCE6C5-DF3A-46C0-A6A6-25C4C5967694

P577

Q57226639-CC45D929-10FA-4F92-BFF0-8B57EB8BF920

P698

Q57226639-E3419316-16E8-45A1-9183-3FAC6B5FBFDE

P356

P1433

Pediatric Blood & Cancer

P1476

RANKL expression is related to ...... lized, high-grade osteosarcoma

@en

P2093

Chang-Bae Kong

http://www.w3.org/2001/XMLSchema#string

Dae-Geun Jeon

http://www.w3.org/2001/XMLSchema#string

Dong Ho Kim

http://www.w3.org/2001/XMLSchema#string

Jae-Soo Koh

http://www.w3.org/2001/XMLSchema#string

Jun Ah Lee

http://www.w3.org/2001/XMLSchema#string

Jun Soo Jung

http://www.w3.org/2001/XMLSchema#string

Jung Sub Lim

http://www.w3.org/2001/XMLSchema#string

Min Suk Kim

http://www.w3.org/2001/XMLSchema#string

Soo-Yong Lee

http://www.w3.org/2001/XMLSchema#string

Wan Hyeong Cho

http://www.w3.org/2001/XMLSchema#string

P2860

Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation

Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups.

Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases.

Denosumab in men receiving androgen-deprivation therapy for prostate cancer

High-dose therapy with autologous stem cell rescue for pediatric sarcomas.

Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis

Biology of breast cancer bone metastasis.

Emerging therapeutic targets in breast cancer bone metastasis.

Increased RANKL expression is related to tumour migration and metastasis of renal cell carcinomas.

RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes.

P304

738-43

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PBC.22720

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

56

http://www.w3.org/2001/XMLSchema#string

P577

2011-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21370405

http://www.w3.org/2001/XMLSchema#string